All In Biotech

Drug Trial Radar · NCT05905614

Phase I Clinical Study of SPH4336 Tablets in the Treatment of Advanced Solid Tumors

An Open-label, Dose-escalation, Phase I Clinical Trial to Explore the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPH4336 Tablets in the Treatment of Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jun 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

29

Actual

Start

Nov 3, 2020

Primary completion

Oct 26, 2023

Study completion Oct 26, 2023

Sponsor

Sponsor type
Industry
First posted
Jun 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical study evaluated the safety and efficacy of SPH4336 in the treatment of advanced solid tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • SPH4336 TabletsDrug

    Open-label SPH4336 Tablets :Administered by oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose(MTD)Time frame: Up to 28 days
  2. Dose-limiting toxicity (DLT)Time frame: Up to 28 days

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University Cancer Hospital

    Beijing, China

  • Chongqing University Cancer Hospital

    Chongqing, China

  • Jinan Central Hospital

    Jinan, Shandong, China

  • West China Hospital,Sichuan University

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.